Worth reading
42Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
5.4
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales23,781¥ millionYear on year +5.4%Progress 92.2%
Operating profit4,272¥ millionYear on year -4.8%Progress 99.3%
Ordinary income4,484¥ millionYear on year -3.7%Progress 101.9%
Net income attributable to owners of the parent3,006¥ millionYear on year -0.2%Progress 105.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥206.37
Operating Margin18.0%
Financial position at period-end
Total assets53,272¥ million
of which net assets 46,781 ¥ millionEquity ratio 87.8%vs. prior year-end +1.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+4,734
Investment-1,293
Financials-1,821
Net change+1,620
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥18,652 million
Regional salesRegion Japan / Current fiscal year ¥19,535,400 thousand / Prior-year period ¥19,031,598 thousand, Region Overseas expansion / Current fiscal year ¥4,246,055 thousand / Prior-year period ¥3,521,640 thousand, Region Total / Current fiscal year ¥23,781,456 thousand / Prior-year period ¥22,553,238 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥25,800 million (YoY +8.5%)
Operating profit¥4,300 million (YoY +0.6%)
Ordinary income¥4,400 million (YoY -1.9%)
Net income¥2,850 million (YoY -5.2%)
Annual Dividend Forecast¥90 → ¥100
Payout ratioActual results 48.5% / Forecast 50.8%
Factors Behind Changes in Business Performance
Operating profit declined due to the impact of higher depreciation associated with capital investment and other factors. Revenue increased due to expanded sales of indwelling intravenous catheters and related products and interventional products.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent eventsNo applicable matters.
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥29,786 thousand / Extraordinary loss Loss on sale of fixed assets ¥758 thousand, Loss on Disposal of Fixed Assets ¥1,030 thousand
Depreciation and amortization¥1,821,836 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End15,880,000 shares
Treasury Shares at Period-End1,401,913 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥23,781 million (YoY +5.4%) |
| Operating profit | ¥4,272 million (YoY -4.8%) |
| Ordinary income | ¥4,484 million (YoY -3.7%) |
| Profit attributable to owners of the parent | ¥3,006 million (YoY -0.2%) |
| Net income per share | ¥206.37 |
| Operating Margin | 18.0% |
| Equity ratio | End of the current fiscal period 87.8 / End of previous period 86.1 |
| Total assets | ¥53,272 million |
| Net assets | ¥46,781 million |
| Cash flows from operating activities | ¥4,734 million |
| Cash flows from investing activities | ¥-1,293 million |
| Cash flows from financing activities | ¥-1,821 million |
| Cash and cash equivalents at end of period | ¥18,652 million |
| Full-year earnings forecast | Net Sales ¥25,800 million (YoY +8.5%) / Operating profit ¥4,300 million (YoY +0.6%) / Ordinary income ¥4,400 million (YoY -1.9%) / Net income ¥2,850 million (YoY -5.2%) |
| Annual Dividend Forecast | ¥90 → ¥100 |
| Payout ratio | Actual results 48.5% / Forecast 50.8% |
| Regional sales | Region Japan / Current fiscal year ¥19,535,400 thousand / Prior-year period ¥19,031,598 thousand, Region Overseas expansion / Current fiscal year ¥4,246,055 thousand / Prior-year period ¥3,521,640 thousand, Region Total / Current fiscal year ¥23,781,456 thousand / Prior-year period ¥22,553,238 thousand |
| Depreciation and amortization | ¥1,821,836 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥29,786 thousand / Extraordinary loss Loss on sale of fixed assets ¥758 thousand, Loss on Disposal of Fixed Assets ¥1,030 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 15,880,000 shares |
| Treasury Shares at Period-End | 1,401,913 shares |
| Factors Behind Changes in Business Performance | Operating profit declined due to the impact of higher depreciation associated with capital investment and other factors. Revenue increased due to expanded sales of indwelling intravenous catheters and related products and interventional products. |
Items this document does not state (5)
Revision to Earnings ForecastShareholder Return PolicySegment revenueSegment profitOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit declined due to the impact of higher depreciation associated with capital investment and other factors. The company cited expanded sales of indwelling intravenous catheters and related products and interventional products as factors contributing to revenue growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.